Why to Avoid Surface Oncology Stock Despite ARK Buying

If you are not paying attention to ARK Investments, you probably should be. ARK invests in what they believe are disruptive innovations. These are technologies and discoveries capable of changing the world and making a fortune for their investors. Recently, an ARK fund bought shares of Surface Oncology (NASDAQ: SURF), a clinical-stage biotechnology company. Should we jump on the bandwagon with this potentially explosive stock? Sadly, the answer is probably not. We'll show you exactly why, including how to find stocks actually worth your money... Read more... Tags: Stocks to Buy The post Why to Avoid Surface Oncology Stock Despite ARK Buying appeared first on Money Morning - We Make Investing Profitable .
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.